Market Research Logo

Seasonal Influenza Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Elderly Population, Growing Awareness and Launch of Quadrivalent Therapies

Seasonal Influenza Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Elderly Population, Growing Awareness and Launch of Quadrivalent Therapies

Summary

Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses, designated as influenza Type A, B, and C. The infection’s rapid onset and potential for high morbidity and mortality, particularly in high-risk patient populations such as the elderly and young children, make prompt and effective treatment with antiviral medication very difficult. For these reasons, prophylactic vaccination is the preferred intervention for seasonal influenza.

In the recent years it was observed that demand for seasonal influenza vaccines have increased due to changed perception of patient population. APAC region is an attractive market for seasonal influenza vaccine manufacturers. Continuous improvements in the formulation of vaccines has occurred over the years, with the market currently transitioning from trivalent to quadrivalent formulations, which offer protection against an additional B strain of the virus. Traditional egg based manufacturing of seasonal influenza vaccines is being replaced with cell culture vaccines. Cell culture based production of vaccines is expected to reduce the problems associated with the production and use of seasonal influenza vaccines which will further increase the vaccination coverage in the APAC region.

GBI Research’s analysis shows that the R&D pipeline for seasonal influenza vaccines comprises a high number of vaccines in early-stage development, many of which are new formulations or those that have been developed using the cell culture method. Late-stage vaccines are either quadrivalent vaccines or pediatric versions of those that have already been approved. GBI Research expects that quadrivalent seasonal influenza vaccines will replace their trivalent vaccines forerunner by the end of the forecast period.

Scope

The seasonal influenza Asia-Pacific market will be valued at $1.71 billion in 2022, growing from $1.24 billion in 2015 at a CAGR of 4.7%.

Trivalent and quadrivalent vaccines dominate the seasonal influenza market, but unmet needs exist in terms of safety and efficacy.

  • Will the drugs under development fulfill the unmet needs of the seasonal influenza market?
  • Do quadrivalent therapies show continuous growth, and are they facing any competition from trivalent therapies?
  • How will available therapies be affected by upcoming pipeline therapies?
The pipeline contains a range of molecule types and molecular targets, including those that are well established in seasonal influenza.
  • Which molecular targets appear most frequently in the pipeline?
  • Will the pipeline drugs fulfill the unmet needs of seasonal influenza market?
Market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value, due to the emergence of quadrivalent therapies.
  • How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
Various drivers and barriers will influence the market over the forecast period.
  • What barriers limit the uptake of premium-priced vaccines in the assessed countries?
  • What factors are most likely to drive the market in these countries?
Reasons to buy

This report will allow you to -
  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the seasonal influenza market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
  • Analyze the seasonal influenza pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict seasonal influenza market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as analysis of the contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the seasonal influenza deals landscape by analyzing trends in licensing and co-development deals.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease Introduction
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology and Pathophysiology
2.4.1 Pathophysiology
2.5 Diagnosis
2.6 Prognosis
2.7 Treatment Options
2.7.1 Treatment Algorithm
2.7.2 Pharmacological Treatments
2.7.3 Non-pharmacological Treatments
2.7.4 Exercise
2.7.5 Dietary Interventions
3 Marketed Products
3.1 Overview
3.2 Fluarix Tetra - GlaxoSmithKline
3.3 FluQuadri - Sanofi Pasteur
3.4 Vaxigrip - Sanofi Pasteur
3.5 Agrippal - CSL
3.6 Fluad - CSL
3.7 Fluvax/Afluria - CSL
3.8 Optaflu - CSL
3.9 Influvac - Abbott
3.10 GC Flu - Green Cross Corporation
3.11 Intanza/IDflu - Sanofi Pasteur
3.12 SkyCellflu - SK Chemicals
3.13 Nasovac-S - Serum Institute of India
3.14 Comparative Efficacy and Safety of Marketed Products
4 Pipeline Analysis
4.1 Overview
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
4.3 Pipeline by Molecular Target
4.4 Promising Pipeline Candidates
4.4.1 VN-100 - Daiichi Sankyo
4.4.2 ASP7374 (UMN-0502) - UMN Pharma
4.4.3 MEDI3250 (VN-0107) - Daiichi Sankyo
4.5 Comparative Efficacy and Safety of Pipeline Products
4.6 Product Competitiveness Framework
5 Clinical Trial Analysis
5.1 Failure Rate
5.1.1 Overall Failure Rate
5.1.2 Failure Rate by Phase and Molecule Type
5.1.3 Failure Rate by Phase and Molecular Target
5.2 Clinical Trial Duration
5.2.1 Clinical Trial Duration by Molecule Type
5.2.2 Clinical Trial Duration by Molecular Target
5.3 Clinical Trial Size
5.3.1 Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development
5.3.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development
5.4 Competitive Clinical Trials Metrics Analysis
6 Multi-scenario Forecast
6.1 Geographical Markets
6.2 Asia-Pacific Market
6.3 India
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Therapy
6.3.3 Market Size
6.4 China
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Therapy
6.4.3 Market Size
6.5 Australia
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Therapy
6.5.3 Market Size
6.6 South Korea
6.6.1 Treatment Usage Patterns
6.6.2 Annual Cost of Therapy
6.6.3 Market Size
6.7 Japan
6.7.1 Treatment Usage Patterns
6.7.2 Annual Cost of Therapy
6.7.3 Market Size
7 Drivers and Barriers
7.1 Drivers
7.1.1 Increasing Awareness and Affordability of Seasonal Influenza Vaccines
7.1.2 Launch of Quadrivalent Influenza Vaccines
7.1.3 Growing Elderly Population
7.1.4 Expansion of Cell-Cultured Vaccines
7.2 Barriers
7.2.1 Limited Awareness of Influenza’s Threat
7.2.2 Unpredictable Vaccine Demand
7.2.3 Influenza Vaccine Safety Concerns
7.2.4 Decentralized Vaccine Policy and Reimbursement System
8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.1.1 Deals by Region and Value
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.1.4 Key Licensing Deals
8.2 Co-Development Deals
8.2.1 Deals by Region and Value
8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.2.4 Key Co-Development Deals
9 Appendix
9.1 All Pipeline Drugs by Stage of Development
9.1.1 Discovery
9.1.2 Preclinical
9.1.3 Phase I
9.1.4 Phase II
9.1.5 Phase III
9.1.6 Pre-registration
9.2 Market Forecasts to 2022
9.2.1 Asia-Pacific
9.2.2 India
9.2.3 China
9.2.4 Australia
9.2.5 South Korea
9.2.6 Japan
9.3 Bibliography
9.4 Abbreviations
9.5 Research Methodology
9.5.1 Secondary Research
9.5.2 Marketed Product Profiles
9.5.3 Late-Stage Pipeline Candidates
9.5.4 Comparative Efficacy and Safety Heatmap for Marketed and Pipeline Products
9.5.5 Product Competitiveness Framework
9.5.6 Pipeline Analysis
9.5.7 Forecasting Model
9.5.8 Deals Data Analysis
9.6 Contact Us
9.7 Disclaimer
1.1 List of Tables
Table 1: Symptoms of Influenza
Table 2: Influenza Testing Methods
Table 3: Influenza Vaccination Recommendation Committees by Country
Table 4: Seasonal Influenza Therapeutics Market, Asia-Pacific, Most Administered Influenza Vaccines by Country
Table 5: Available Antiviral Drugs for Seasonal Influenza
Table 6: Seasonal Influenza Therapeutics Market, Global, All Pipeline Products, Discovery, 2016
Table 7: Seasonal Influenza Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016
Table 8: Seasonal Influenza Therapeutics Market, Global, All Pipeline Products, Phase I, 2016
Table 9: Seasonal Influenza Therapeutics Market, Global, All Pipeline Products, Phase II, 2016
Table 10: Seasonal Influenza Therapeutics Market, Global, All Pipeline Products, Phase III, 2016
Table 11: Seasonal Influenza Therapeutics Market, Global, All Pipeline Products, Pre-registration Phase, 2016
Table 12: Seasonal influenza Therapeutics Market, Asia-Pacific, Market Forecast, 2015-2022
Table 13: Seasonal Influenza Therapeutics Market, India, Market Forecast, 2015-2022
Table 14: Seasonal Influenza Therapeutics Market, China, Market Forecast, 2015-2022
Table 15: Seasonal Influenza Therapeutics Market, Australia, Market Forecast, 2015-2022
Table 16: Seasonal Influenza Therapeutics Market, South Korea, Market Forecast, 2015-2022
Table 17: Seasonal Influenza Therapeutics Market, Japan, Market Forecast, 2015-2022
1.2 List of Figures
Figure 1: Notifications of Laboratory-Confirmed Influenza, Australia, 2012-July 2016
Figure 2: Seasonal Influenza Therapeutics Market, Treatment Algorithm of Seasonal Influenza
Figure 3: Seasonal Influenza Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products for Treatment of Seasonal Influenza
Figure 4: Pipeline for Seasonal Influenza Therapeutics by Molecular Type, Global, 2016
Figure 5: Pipeline for Seasonal Influenza Therapeutics by Molecular Target, Global, 2016
Figure 6: Seasonal Influenza Therapeutics Market, Asia-Pacific, VN-100 ($m), 2017-2022
Figure 7: Seasonal Influenza Therapeutics Market, Asia-Pacific, ASP7374 ($m), 2017-2022
Figure 8: Seasonal Influenza Therapeutics Market, Asia-Pacific, MEDI3250 ($m), 2017-2022
Figure 9: Seasonal Influenza Therapeutics Market, Comparative Efficacy Heatmap for Pipeline Products
Figure 10: Seasonal Influenza Therapeutics Market, Global, Competitor Matrix for Marketed and Pipeline Products, 2016
Figure 11: Seasonal Influenza Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2006-2016
Figure 12: Seasonal Influenza Therapeutics, Global, Clinical Trial Failure Rates by Molecule Type (%), 2006-2016
Figure 13: Seasonal Influenza Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2006-2016
Figure 14: Seasonal Influenza Therapeutics, Global, Clinical Trial Duration by Molecule Type, 2006-2016
Figure 15: Seasonal Influenza Therapeutics, Global, Clinical Trial Duration by Molecular Target, 2006-2016
Figure 16: Seasonal Influenza Therapeutics, Global, Clinical Trial Size per Product by Molecule Type, 2006-2016
Figure 17: Seasonal Influenza Therapeutics, Global, Clinical Trial Size per Product by Molecular Target, 2006-2016
Figure 18: Seasonal Influenza Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type, 2006-2016
Figure 19: Seasonal Influenza Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target, 2006-2016
Figure 20: Seasonal Influenza Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
Figure 21: Seasonal Influenza Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
Figure 22: Seasonal Influenza Therapeutics Market, Asia-Pacific, Treatment Patterns (million), 2015-2022
Figure 23: Seasonal Influenza Therapeutics Market, Asia-Pacific, Market Size ($bn), 2015-2022
Figure 24: Seasonal Influenza Therapeutics Market, India, Treatment Patterns (million), 2015-2022
Figure 25: Seasonal Influenza Therapeutics Market, India, Annual Cost of Therapy ($), 2015-2022
Figure 26: Seasonal Influenza Therapeutics Market, India, Market Size ($m), 2015-2022
Figure 27: Seasonal Influenza Therapeutics Market, China, Treatment Patterns (million), 2015-2022
Figure 28: Seasonal Influenza Therapeutics Market, China, Annual Cost of Therapy ($), 2015-2022
Figure 29: Seasonal Influenza Therapeutics Market, China, Market Size ($m), 2015-2022
Figure 30: Seasonal Influenza Therapeutics Market, Australia, Treatment Patterns (million), 2015-2022
Figure 31: Seasonal Influenza Therapeutics Market, Australia, Annual Cost of Therapy ($), 2015-2022
Figure 32: Seasonal Influenza Therapeutics Market, Australia, Market Size ($m), 2015-2022
Figure 33: Seasonal Influenza Therapeutics Market, South Korea, Treatment Patterns (million), 2015-2022
Figure 34: Seasonal Influenza Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2015-2022
Figure 35: Seasonal Influenza Therapeutics Market, South Korea, Market Size ($m), 2015-2022
Figure 36: Seasonal Influenza Therapeutics Market, Japan, Treatment Patterns (million), 2015-2022
Figure 37: Seasonal Influenza Therapeutics Market, Japan, Annual Cost of Therapy ($), 2015-2022
Figure 38: Seasonal Influenza Therapeutics Market, Japan, Market Size ($m), 2015-2022
Figure 39: Seasonal Influenza Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2016
Figure 40: Seasonal Influenza Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2016
Figure 41: Seasonal Influenza Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2016
Figure 42: Seasonal Influenza Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006-2016
Figure 43: Seasonal Influenza Therapeutics Market, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2006-2016
Figure 44: Seasonal Influenza Therapeutics Market, Global, Co-development Deals by Region, 2006-2016
Figure 45: Seasonal Influenza Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2016
Figure 46: Seasonal Influenza Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2016
Figure 47: Seasonal Influenza Therapeutics Market, Global, Co-development Deals by Molecule Type and Stage of Development, 2006-2016
Figure 48: Seasonal Influenza Therapeutics Market, Global, Co-development Deals by Molecular Target, 2006-

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report